Gyre Therapeutics Sets CEO Ying Luo’s Annual Base Salary at $500,000

By Public Technologies
  • Gyre Therapeutics entered new employment agreements with CEO Ying Luo and CFO Thomas Eastling on October 16, 2026.
  • Luo receives a $500,000 annual base salary, with a target bonus of $150,000 for 2026.
  • Eastling receives a $339,066 annual base salary, with a target bonus of $70,000.
  • Termination without cause or resignation for good reason triggers base salary paid over six months, COBRA reimbursement and partial accelerated equity vesting.
  • Qualifying terminations within three months before or 12 months after a change of control trigger lump-sum salary-and-bonus payments, full equity vesting.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-040506), on October 22, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk